SCHEMBL3563479

SCHEMBL3563479

CC(C)Oc1ccc(-c2cc(CC(=O)O)cc(OCc3ccccc3)c2)cc1

nearest known ligand 0.60

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MCL1 Q07820 3/20 0.60
PPARD Q03181 3/20 0.51
PPARG P37231 3/20 0.51
LTB4R Q15722 2/20 0.51
LTB4R2 Q9NPC1 2/20 0.51
LMNA P02545 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
FFAR4 Q5NUL3 1/20 0.47
PTGDR Q13258 1/20 0.46
GSTP1 P09211 1/20 0.46
EDNRA P25101 1/20 0.46
FFAR1 O14842 2/20 0.46
ACACB O00763 1/20 0.46
MMP12 P39900 1/20 0.46
CNR2 P34972 1/20 0.45
PPARA Q07869 1/20 0.45
MAOB P27338 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3579322 0.91 CFD (0.52) MCL1PPARDPPARGLTB4RLTB4R2
SCHEMBL3569849 0.86 PPARD (0.56) MCL1PPARDPPARGLTB4RLTB4R2
SCHEMBL3569632 0.86 PPARG (0.62) MCL1PPARDPPARGLTB4RLTB4R2
SCHEMBL3575842 0.85 FFAR1 (0.55) MCL1PPARDPPARGLTB4RLTB4R2
SCHEMBL3578107 0.85 PPARG (0.55) MCL1PPARDPPARGLTB4RLTB4R2
SCHEMBL3572558 0.83 PPARD (0.53) MCL1PPARDPPARGLTB4RLTB4R2
SCHEMBL3576743 0.83 MRGPRX4 (0.54) MCL1PPARDPPARGLTB4RLTB4R2
SCHEMBL3574622 0.81 LTB4R (0.51) MCL1PPARDPPARGLTB4RLTB4R2
SCHEMBL3570631 0.81 PPARD (0.57) PPARDPPARGLTB4RLTB4R2FFAR4
SCHEMBL3568711 0.80 MEN1 (0.54) PPARDPPARGLTB4RLTB4R2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7825160-B2 such as [5-(4-Fluoro-benzyloxy)-4'-trifluoromethyl-biphenyl-3-yl]-acetic acid, used for the treatment of Alzheimer's disease and for the modulation of gamma -secretase activity CELLZOME LIMITED (GB) 2010-11-02 US claimed
US-20090118289-A1 (Biphenyl) Carboxylic Acids and Derivatives Thereof CELLZOME AG (DE) 2009-05-07 US claimed
EP-1805129-B1 (BIPHENYL) CARBOXYLIC ACIDS AND DERIVATIVES THEREOF CELLZOME LTD (GB) 2009-03-18 EP claimed
EP-1805129-A1 (BIPHENYL) CARBOXYLIC ACIDS AND DERIVATIVES THEREOF CELLZOME AG (DE) 2007-07-11 EP claimed
WO-2006045554-A1 (BIPHENYL) CARBOXYLIC ACIDS AND DERIVATIVES THEREOF CELLZOME AG (DE) 2006-05-04 WO claimed
US-7825160-B2 such as [5-(4-Fluoro-benzyloxy)-4'-trifluoromethyl-biphenyl-3-yl]-acetic acid, used for the treatment of Alzheimer's disease and for the modulation of gamma -secretase activity CELLZOME LIMITED (GB) 2010-11-02 US disclosed
US-20090118289-A1 (Biphenyl) Carboxylic Acids and Derivatives Thereof CELLZOME AG (DE) 2009-05-07 US disclosed
EP-1805129-B1 (BIPHENYL) CARBOXYLIC ACIDS AND DERIVATIVES THEREOF CELLZOME LTD (GB) 2009-03-18 EP disclosed
EP-1805129-A1 (BIPHENYL) CARBOXYLIC ACIDS AND DERIVATIVES THEREOF CELLZOME AG (DE) 2007-07-11 EP disclosed
WO-2006045554-A1 (BIPHENYL) CARBOXYLIC ACIDS AND DERIVATIVES THEREOF CELLZOME AG (DE) 2006-05-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090118289-A1 (Biphenyl) Carboxylic Acids and Derivatives Thereof BACE1, BACE2, APP MCL1 3306/4885PPARD 455/4885PPARG 239/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.